Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGT1 | P19440 | 1/20 | 0.58 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.47 |
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.42 |
| ▸ | CPB1 | P15086 | 1/20 | 0.40 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CTH | P32929 | 1/20 | 0.34 |
| ▸ | MME | P08473 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28581575 | 1.00 | GGT1 (0.58) | GGT1TGFBR1CPB2CPB1GABRR1 | |
| SCHEMBL1251584 | 0.87 | GGT1 (0.46) | GGT1TGFBR1CPB2GABRR1FOLH1 | |
| SCHEMBL27813660 | 0.87 | GGT1 (0.46) | GGT1TGFBR1CPB2GABRR1FOLH1 | |
| SCHEMBL2163628 | 0.83 | GGT1 (0.65) | GGT1TGFBR1CPB2CPB1GABRR1 | |
| SCHEMBL19514753 | 0.82 | GGT1 (0.69) | GGT1CPB2CPB1GABRR1FOLH1 | |
| SCHEMBL8894811 | 0.82 | GGT1 (0.44) | GGT1TGFBR1CPB2CPB1 | |
| SCHEMBL8894803 | 0.82 | GGT1 (0.44) | GGT1TGFBR1CPB2CPB1 | |
| SCHEMBL27832611 | 0.81 | — | — | |
| SCHEMBL27832608 | 0.81 | — | — | |
| SCHEMBL11836455 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442788-B2 | Antisense molecules and method of controlling expression of gene function by using the same | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2008-10-28 | — | — | US | claimed |
| US-6872809-B2 | Nucleoside derivatives | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2005-03-29 | — | — | US | claimed |
| US-20030208050-A1 | Nucleoside derivatives | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2003-11-06 | — | — | US | claimed |
| US-20030162739-A1 | Antisense molecules and method of controlling expression of gene function by using the same | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2003-08-28 | — | — | US | claimed |
| EP-1295892-A1 | ANTISENSE MOLECULES AND METHOD OF CONTROLLING EXPRESSION OF GENE FUNCTION BY USING THE SAME | Japan Science and Technology Corporation (JP) | 2003-03-26 | — | — | EP | claimed |
| EP-1295891-A1 | NUCLEOSIDE DERIVATIVES | Japan Science and Technology Corporation (JP) | 2003-03-26 | — | — | EP | claimed |
| US-20240018110-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | ALPHA-9 ONCOLOGY INC. (CA) | 2024-01-18 | — | — | US | disclosed |
| EP-4263509-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | The University of British Columbia (CA) | 2023-10-25 | — | — | EP | disclosed |
| WO-2022126275-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2022-06-23 | — | — | WO | disclosed |
| EP-1423400-B2 | EVOLVING NEW MOLECULAR FUNCTION | HARVARD COLLEGE (US) | 2013-05-22 | — | — | EP | disclosed |
| US-20120165228-A1 | EVOLVING NEW MOLECULAR FUNCTION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2012-06-28 | — | — | US | disclosed |
| EP-2433935-A1 | Substituted-quinoxaline-type-piperidine compounds and the uses thereof | Purdue Pharma LP (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-2433936-A1 | Substituted-quinoxaline-type-piperidine compounds and the uses thereof | Purdue Pharma LP (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20030162739-A1 | Antisense molecules and method of controlling expression of gene function by using the same | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2003-08-28 | — | — | US | disclosed |
| US-20030113738-A1 | Evolving new molecular function | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2003-06-19 | — | — | US | disclosed |
| EP-1295892-A1 | ANTISENSE MOLECULES AND METHOD OF CONTROLLING EXPRESSION OF GENE FUNCTION BY USING THE SAME | Japan Science and Technology Corporation (JP) | 2003-03-26 | — | — | EP | disclosed |
| EP-1295891-A1 | NUCLEOSIDE DERIVATIVES | Japan Science and Technology Corporation (JP) | 2003-03-26 | — | — | EP | disclosed |
| EP-1295891-A1 | NUCLEOSIDE DERIVATIVES | Japan Science and Technology Corporation (JP) | 2003-03-26 | — | — | EP | disclosed |
| WO-2002074929-A2 | EVOLVING NEW MOLECULAR FUNCTION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2002-09-26 | — | — | WO | disclosed |
| WO-2001096355-A1 | NUCLEOSIDE DERIVATIVES | JAPAN SCIENCE AND TECHNOLOGY CORPORATION (JP) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162739-A1 | Antisense molecules and method of controlling expression of gene function by using the same | RNGTT, RNMT, UPF1 | GGT1 2807/4885TGFBR1 4470/4885CPB2 2425/4885 |
| US-20030208050-A1 | Nucleoside derivatives | RIMKLA, MTHFD1, AADAT | GGT1 279/4885TGFBR1 2081/4885CPB2 1928/4885 |
| US-20240018110-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | KLK3, FOLH1, TMEM14C | GGT1 464/4885TGFBR1 4478/4885CPB2 1056/4885 |
| US-20120165228-A1 | EVOLVING NEW MOLECULAR FUNCTION | POLI, PCNA, POLK | GGT1 3686/4885TGFBR1 4368/4885CPB2 1560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.